Comparative Pharmacology
Head-to-head clinical analysis: HERCESSI versus TRAZIMERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HERCESSI versus TRAZIMERA.
HERCESSI vs TRAZIMERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It inhibits the proliferation of human tumor cells that overexpress HER2, and mediates antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing cancer cells.
Trazimera is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumor cells overexpressing HER2 and mediates antibody-dependent cellular cytotoxicity (ADCC).
10 mg subcutaneously daily for 21 consecutive days, followed by 7 days off therapy in 28-day cycles.
For HER2-positive breast cancer, the recommended dose is 8 mg/kg intravenous infusion over 90 minutes on day 1 of cycle 1, followed by 6 mg/kg over 30-90 minutes every 3 weeks for the duration of therapy.
None Documented
None Documented
Terminal elimination half-life is 2.5–3.5 hours (mean ~3 hours) in patients with normal renal function; prolonged to 6–12 hours in moderate renal impairment and up to 20 hours in severe impairment.
Terminal elimination half-life approximately 28 days (range 20–38 days) based on population pharmacokinetic analysis.
Primarily excreted unchanged in urine via glomerular filtration and active tubular secretion; ~90% of dose recovered in urine as parent drug, ~5% in feces.
Primarily via the reticuloendothelial system. Mean clearance 0.225 L/day. Elimination half-life is not dose-dependent.
Category C
Category C
HER2 Inhibitor
HER2 Inhibitor